Considering tocilizumab preventing IL-6 itself from binding to its receptor and alleviating the inflammatory responses 1, we explored the changes of inflammatory hallmarks in tocilizumab users with severe/critical COVID-19. This evidence concerns the gene IL6 and COVID-19.